Mesothelioma in australia: A review

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

∙ The incidence of malignant mesothelioma in Australia is among the highest in the world as a result of widespread use of asbestos by industry and in construction throughout the 20th century. ∙ The risk of developing malignant mesothelioma after asbestos exposure is dose-related; a transient, low dose exposure confers a correspondingly very low risk of disease. ∙ Malignant mesothelioma is a heterogeneous disease, partly explaining the limited role of biomarkers in screening and diagnosis. ∙ The prognosis remains poor, and early advice on medico-legal compensation and a collaborative team approach to managing malignant mesothelioma are both essential. ∙ Chemotherapy can have a modest treatment effect in some people. New therapies, such as immunotherapy, do not yet have a defined role in the treatment of malignant mesothelioma. ∙ As treatment options for malignant mesothelioma are limited and no cure is available, there is no established role for early detection or screening of at risk populations. ∙ A multidisciplinary approach to caring for patients with malignant mesothelioma and their carers is vital.

Original languageEnglish
Pages (from-to)449-452
Number of pages4
JournalMedical Journal of Australia
Volume207
Issue number10
DOIs
Publication statusPublished - 20 Nov 2017

Fingerprint Dive into the research topics of 'Mesothelioma in australia: A review'. Together they form a unique fingerprint.

  • Cite this